8-K: Bolt Biotherapeutics Holds Annual Meeting, Elects Directors

Bolt Biotherapeutics announced the results of its 2026 annual meeting of stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Summary

• Bolt Biotherapeutics, Inc. held its 2026 annual meeting of stockholders on June 10, 2026.
• The meeting addressed three proposals, as detailed in the company's definitive proxy statement.
• A total of 1,921,567 shares were eligible to vote as of April 22, 2026.
• 877,358 shares were represented at the meeting.
• William P. Quinn and Jakob Dupont, M.D. were elected as Class II directors.
• They will serve until the 2029 Annual Meeting of Stockholders or until their successors are elected.
• PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports on routine corporate governance matters without significant new strategic information or financial performance indicators.

Positives

• Successful election of two Class II directors to the board.
• Ratification of PricewaterhouseCoopers LLP as the independent auditor, indicating continued confidence in their services.
• A significant portion of eligible shares (approximately 45.6%) were represented at the meeting, suggesting stockholder engagement.

Negatives

• A notable number of broker non-votes (475,883) for director nominees, which could indicate a lack of direct shareholder instruction on these matters.
• A substantial number of votes withheld for William P. Quinn (52,117), potentially signaling some shareholder dissent.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the election of directors and auditor ratification for the upcoming fiscal year.

Management Comments

• William P. Quinn, President, Chief Executive Officer and Chief Financial Officer, signed the report on behalf of the company.

Industry Context

StockSavvy.ai notes that annual meetings and director elections are standard corporate governance events for publicly traded companies, reflecting the ongoing oversight and accountability mechanisms within the biotechnology sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and auditor ratification directly impacts shareholder representation and confidence in financial reporting.
• Board of Directors: The election of new directors ensures the board's continued functioning and governance.
• Employees: Stability in leadership and audit oversight can contribute to a stable operating environment.

Next Steps

• The newly elected Class II directors will serve their terms until the 2029 Annual Meeting.
• PricewaterhouseCoopers LLP will serve as the independent registered public accounting firm for the year ending December 31, 2026.

Key Dates

Keywords

Bolt Biotherapeutics, Annual Meeting, Stockholder Meeting, Director Election, Independent Auditor, Corporate Governance, SEC Filing, Form 8-K